HK1255839A1 - 與人crth2特異性結合的抗體 - Google Patents
與人crth2特異性結合的抗體Info
- Publication number
- HK1255839A1 HK1255839A1 HK18114915.3A HK18114915A HK1255839A1 HK 1255839 A1 HK1255839 A1 HK 1255839A1 HK 18114915 A HK18114915 A HK 18114915A HK 1255839 A1 HK1255839 A1 HK 1255839A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibody
- specifically binds
- human crth2
- crth2
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015141633 | 2015-07-15 | ||
PCT/JP2016/071027 WO2017010567A1 (ja) | 2015-07-15 | 2016-07-15 | ヒトcrth2に特異的に結合する抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1255839A1 true HK1255839A1 (zh) | 2019-08-30 |
Family
ID=57757419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18114915.3A HK1255839A1 (zh) | 2015-07-15 | 2018-11-22 | 與人crth2特異性結合的抗體 |
Country Status (10)
Country | Link |
---|---|
US (3) | US9938349B2 (zh) |
EP (1) | EP3323832A4 (zh) |
JP (2) | JP6309050B2 (zh) |
KR (1) | KR20180030030A (zh) |
CN (1) | CN107849139B (zh) |
AU (1) | AU2016293807B2 (zh) |
CA (1) | CA2992262A1 (zh) |
HK (1) | HK1255839A1 (zh) |
TW (1) | TWI726897B (zh) |
WO (1) | WO2017010567A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11208491B2 (en) | 2017-01-24 | 2021-12-28 | Kyowa Kirin Co., Ltd. | Treatment or prevention method of radiation damage by administration of IL-5 receptor alpha chain binding antibody |
CN107779500A (zh) * | 2017-10-25 | 2018-03-09 | 上海药明生物技术有限公司 | 一种快速获取大鼠杂交瘤细胞单克隆抗体序列的测序方法及引物序列 |
WO2019169015A1 (en) * | 2018-02-27 | 2019-09-06 | Equillium, Inc. | Anti cd6 antibodies for treating severe asthma |
TW202039581A (zh) * | 2018-12-28 | 2020-11-01 | 日商協和麒麟股份有限公司 | 與TfR結合之雙專一性抗體 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0851030B9 (en) * | 1996-06-05 | 2007-10-31 | BML Inc. | PROTEIN SPECIFIC TO HUMAN Th2, GENE (B19) ENCODING THE SAME, AND TRANSFORMANT, RECOMBINANT VECTOR AND MONOCLONAL ANTIBODY RELATING THERETO |
WO2005093092A2 (en) * | 2004-03-26 | 2005-10-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44) |
US20140328849A1 (en) * | 2013-03-15 | 2014-11-06 | Genentech, Inc. | Anti-crth2 antibodies and methods of use |
-
2016
- 2016-07-15 TW TW105122490A patent/TWI726897B/zh active
- 2016-07-15 AU AU2016293807A patent/AU2016293807B2/en active Active
- 2016-07-15 JP JP2016140458A patent/JP6309050B2/ja active Active
- 2016-07-15 WO PCT/JP2016/071027 patent/WO2017010567A1/ja active Application Filing
- 2016-07-15 CA CA2992262A patent/CA2992262A1/en active Pending
- 2016-07-15 EP EP16824547.0A patent/EP3323832A4/en active Pending
- 2016-07-15 KR KR1020187000812A patent/KR20180030030A/ko not_active Application Discontinuation
- 2016-07-15 CN CN201680041608.6A patent/CN107849139B/zh active Active
- 2016-11-03 US US15/342,534 patent/US9938349B2/en active Active
-
2018
- 2018-02-16 US US15/932,185 patent/US10100120B2/en active Active
- 2018-03-12 JP JP2018044483A patent/JP2018138546A/ja active Pending
- 2018-09-07 US US16/124,706 patent/US20180371100A1/en not_active Abandoned
- 2018-11-22 HK HK18114915.3A patent/HK1255839A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016293807B2 (en) | 2022-03-17 |
US20180371100A1 (en) | 2018-12-27 |
AU2016293807A1 (en) | 2018-02-08 |
US10100120B2 (en) | 2018-10-16 |
US20180222994A1 (en) | 2018-08-09 |
TWI726897B (zh) | 2021-05-11 |
CN107849139B (zh) | 2022-05-03 |
KR20180030030A (ko) | 2018-03-21 |
JP2018138546A (ja) | 2018-09-06 |
JP2017038592A (ja) | 2017-02-23 |
US9938349B2 (en) | 2018-04-10 |
EP3323832A1 (en) | 2018-05-23 |
TW201704262A (zh) | 2017-02-01 |
WO2017010567A1 (ja) | 2017-01-19 |
US20170121415A1 (en) | 2017-05-04 |
EP3323832A4 (en) | 2018-12-26 |
JP6309050B2 (ja) | 2018-04-11 |
CN107849139A (zh) | 2018-03-27 |
CA2992262A1 (en) | 2017-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285287B1 (en) | Antibodies to tigit | |
IL267798B (en) | Human antibodies to pd-1 | |
IL261188A (en) | Antibodies against tigit | |
IL246661B (en) | Human antibodies to pd–l1 | |
GB201508180D0 (en) | Antibodies | |
PT3101132T (pt) | Anticorpo humano anti-transtirretina | |
PL3180356T3 (pl) | Ludzkie przeciwciało anty-fgfr4 | |
EP3551228A4 (en) | ANTIBODIES FOR HUMAN ALPHA SYNUCLEIN | |
HK1255839A1 (zh) | 與人crth2特異性結合的抗體 | |
GB201609742D0 (en) | Improvements relating to antibodies | |
GB201509907D0 (en) | Antibodies | |
HK1212719A1 (zh) | 全人源抗 抗體 | |
GB201509493D0 (en) | Therapeutic antibody | |
GB201515572D0 (en) | Anti-LAG-3 antibodies | |
GB201515570D0 (en) | Anti-LAG-3 antibodies | |
GB201514425D0 (en) | Antibodies | |
GB201508437D0 (en) | Antibodies | |
GB201508444D0 (en) | Antibodies | |
GB201507541D0 (en) | Antibodies | |
GB201504858D0 (en) | Antibodies | |
GB201502591D0 (en) | Antibodies |